Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel for Desmoid Tumors, DSRCT and Ewing Sarcoma
NCT03275818Phase 2Completed
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- May 2017
- Primary completion
- Sep 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nab-paclitaxel in desmoid tumor, desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (2 cohorts), sponsored by Spanish Group for Research on Sarcoma. Primary endpoints: Overall Response Rate at 3 months, Objective Response Rate at 2 months and 1 more. Started May 2017; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
desmoid tumordesmoplastic small round cell tumor (DSRCT)Ewing sarcoma
Beyond the preview
Go deeper on NCT03275818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275818.